Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant

Biochem Biophys Res Commun. 2004 Jul 2;319(3):733-7. doi: 10.1016/j.bbrc.2004.05.051.

Abstract

Alzheimer's disease (AD) is a neurodegenerative affliction associated with memory dysfunction. Senile plaques are a pathological hallmark of AD, and amyloid beta (Abeta) peptides are a major component of these plaques. Abeta peptides are derived from proteolytic cleavage of the Abeta protein precursor (APP) by beta- and gamma-secretases to generate two principal species, Abeta1-40 and Abeta1-42. We have developed antibodies against the N- and C-termini of these peptides, and an ELISA for accurate and sensitive quantitative assessment. Sandwich ELISA composed of N-terminus (Abeta1) end-specific antibody, clone 82E1, and C-termini end-specific antibodies, and clones 1A10 and 1C3 for Abeta40 and Abeta42, respectively, detects full-length Abeta1-40 and 1-42 with a sensitivity in the sub single digit fmol/ml (equivalent to single digit pg/ml) range with no cross-reactivity to APP. A combination of C-termini antibodies and an antibody against the middle region of Abeta detects mouse Abeta in non-transgenic mouse brains.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / blood
  • Amyloid beta-Peptides / immunology
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Antibodies / metabolism*
  • Brain / cytology
  • Brain / metabolism
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peptide Fragments / immunology
  • Peptide Fragments / metabolism*

Substances

  • Amyloid beta-Peptides
  • Antibodies
  • Peptide Fragments